 Psoriasis is associated with a greater risk of incident venous thromboembolism: the Iowa Women's Health Study
 31.03.2012 12:22  8995351 views  0 comments
 (Source: Journal of Thrombosis and Haemostasis) Read more »
| Weight loss alone not sufficient to maintain psoriasis remission
31.03.2012 9:28 9078861 views 0 comments
 Weight loss alone is not sufficient for maintenance of moderate-to-severe psoriasis in obese individuals, suggest study results. (Source: MedWire News - Psoriasis) Read more »
| PodMed: A Medical News Roundup from Johns Hopkins (with audio)
30.03.2012 19:43 8980349 views 0 comments
 (MedPage Today) -- This week's topics include antibodies for psoriasis, where it's safe to get a stent placed, bypass surgery versus stents, and bariatric surgery for diabetes. (Source: MedPage Today Primary Care) Read more »
| Talking About Your Psoriasis to Others
29.03.2012 15:56 9505950 views 0 comments
 Most people don't know much about psoriasis, and some may fear it's contagious. Here are 6 tips to help you talk about your psoriasis to others. (Source: WebMD Health) Read more »
| HLA alleles in Brazilian patients with fissured tongue
28.03.2012 22:00 8983209 views 0 comments
 Conclusion The lack of association of FT with HLA‐C*06 reinforces the proposal that this disease does not have a common genetic factor in the triad of BMG, FT and PS. (Source: Journal of the European Academy of Dermatology and Venereology) Read more »
| IL-17 New Target in Psoriasis (CME/CE)
28.03.2012 21:13 9877396 views 0 comments
 (MedPage Today) -- Targeting the interleukin (IL)-17 signaling pathway may provide an effective and specific treatment approach for patients with moderate-to-severe plaque psoriasis, two multicenter randomized phase II trials suggested. (Source: MedPage Today Dermatology) Read more »
| Comparison of Skindex‐29, Dermatology Life Quality Index, Psoriasis Disability Index and Medical Outcome Study Short Form 36 in patients with mild to severe psoriasis
28.03.2012 21:08 9933334 views 0 comments
Tags: Live, India, British, Ford, Shows, Study, Journey, Medical, Psoriasis, Dermatology, QualityFrom:
www.medworm.com
Conclusions Skindex‐29 has better sensitivity to clinical severity with minimal floor effect, and covers the main domains explored by the other three QoL instruments in patients with mild to severe psoriasis. (Source: British Journal of Dermatology) Read more »
| Long‐term efficacy of ustekinumab in patients with moderate‐to‐severe psoriasis: results from the PHOENIX 1 trial through up to 3 years
28.03.2012 21:08 9330546 views 0 comments
 Conclusions Continuous, stable, maintenance dosing with ustekinumab was generally well tolerated and sustained durable efficacy for up to 3 years of treatment. (Source: British Journal of Dermatology) Read more »
| Psoriasis and risk of nonfatal cardiovascular disease in U.S. women: a cohort study
28.03.2012 21:08 8879597 views 0 comments
 Conclusions Psoriasis is an independent predictor for nonfatal CVD among women, with particularly high risk for those with longer duration of psoriasis and concomitant psoriatic arthritis. (Source: British Journal of Dermatology) Read more »
| The inflammatory markers in psoriasis – reply from authors
28.03.2012 21:00 9178271 views 0 comments
 (Source: British Journal of Dermatology) Read more »
| Anti–Interleukin-17 Monoclonal Antibody Ixekizumab in Chronic Plaque Psoriasis
28.03.2012 21:00 9204422 views 0 comments
 New England Journal of Medicine, Volume 366, Issue 13, Page 1190-1199, March 2012. (Source: New England Journal of Medicine) Read more »
| Brodalumab, an Anti–Interleukin-17–Receptor Antibody for Psoriasis
28.03.2012 21:00 9646484 views 0 comments
 New England Journal of Medicine, Volume 366, Issue 13, Page 1181-1189, March 2012. (Source: New England Journal of Medicine) Read more »
| To Be 17 Again — Anti–Interleukin-17 Treatment for Psoriasis
28.03.2012 21:00 9004576 views 0 comments
 New England Journal of Medicine, Volume 366, Issue 13, Page 1251-1252, March 2012. (Source: New England Journal of Medicine) Read more »
| Biologic Treatments May Ease Psoriasis
28.03.2012 5:00 9481107 views 0 comments
Two experimental biologic treatments may help treat psoriasis, researchers report in The New England Journal of Medicine. (Source: WebMD Health) Read more »
| The inflammatory markers in psoriasis
28.03.2012 4:00 9801203 views 0 comments
 (Source: British Journal of Dermatology) Read more »
| Topical valrubicin application reduces skin inflammation in murine models
28.03.2012 4:00 9679021 views 0 comments
 Conclusion: The present data documents an anti‐inflammatory effect of valrubicin, and may suggest an interesting new role for valrubicin in other debilitating skin diseases in which inflammation is a significant factor. (Source: British Journal of Dermatology) Read more »
| Etanercept suppresses regenerative hyperplasia in psoriasis by acutely downregulating epidermal expression of IL‐19, IL‐20 and IL‐24
28.03.2012 4:00 9433649 views 0 comments
Conclusions: Based on the rapid suppression of regenerative hyperplasia, chemokines, and other keratinocyte‐derived products, including the IL‐20 subfamily, we propose that epidermal activation is a very early target of etanercept. As many of these keratinocyte markers are stimulated by TNF‐α, their rapid downregulation likely reflects etanercept’s antagonism of TNF‐α. Additionally, decreased epidermal hyperplasia might result specifically from acute suppression of the IL‐20 subfamily, which is also a likely consequence of etanercept’s antagonism of TNF‐α. Thus, the IL‐20 subfamily has potential importance in the pathogenesis of psoriasis and therapeutic response to etanercept. (Source: British Journal of Dermatology) Read more »
| Two Experimental Drugs Could Improve Psoriasis Treatment
28.03.2012 4:00 8842780 views 0 comments
 Both medications reduced skin lesions, had few side effects, studies show (Source: Primary Care News - Doctors Lounge) Read more »
| Coffee, caffeine not tied to psoriasis
28.03.2012 4:00 9461369 views 0 comments
 A new study suggests that coffee and caffeine are not associated with psoriasis incidence after
adjustment for smoking. (Source: Modern Medicine) Read more »
| Adalimumab also reduces vascular inflammation
27.03.2012 14:07 27004400 views 0 comments
 Results of a new pilot study suggest that adalimumab, a tumor necrosis factor inhibitor for the
treatment of psoriasis, also reduces vascular inflammation seen in patients with concomitant coronary
atherosclerosis. (Source: Modern Medicine) Read more »
|
Older news »
|
|
|
